Last reviewed · How we verify
Meningococcal vaccine GSK134612
Meningococcal vaccine GSK134612 is a Recombinant protein vaccine Biologic drug developed by GlaxoSmithKline. It is currently in Phase 3 development for Prevention of meningococcal serogroup B disease in infants and children. Also known as: Nimenrix®, MenACWY-TT, Nimenrix.
This vaccine stimulates the immune system to produce antibodies against meningococcal serogroup B antigens, providing protection against meningococcal disease.
This vaccine stimulates the immune system to produce antibodies against meningococcal serogroup B antigens, providing protection against meningococcal disease. Used for Prevention of meningococcal serogroup B disease in infants and children.
At a glance
| Generic name | Meningococcal vaccine GSK134612 |
|---|---|
| Also known as | Nimenrix®, MenACWY-TT, Nimenrix |
| Sponsor | GlaxoSmithKline |
| Drug class | Recombinant protein vaccine |
| Target | Neisseria meningitidis serogroup B surface antigens |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
GSK134612 is a recombinant meningococcal serogroup B vaccine designed to elicit both humoral and cellular immune responses against key surface antigens of Neisseria meningitidis serogroup B. By priming the adaptive immune system to recognize and respond to meningococcal pathogens, the vaccine reduces the risk of invasive meningococcal disease including meningitis and septicemia.
Approved indications
- Prevention of meningococcal serogroup B disease in infants and children
Common side effects
- Injection site pain/erythema
- Fever
- Irritability
- Drowsiness
Key clinical trials
- Immunogenicity and Safety Study of 1 and 2 Doses of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine MenACWY-TT (GSK134612) in Toddlers, Persistence up to 5 Years After Vaccination and Co-administration With Pfizer's Prevenar 13™Vaccine (PHASE3)
- Study to Evaluate Persistence of Antibodies After Vaccination With Meningococcal Vaccine GSK134612 (PHASE3)
- Immunogenicity and Safety of Meningococcal Vaccine GSK 134612 Co-administered With Pneumococcal and DTPa-HBV-IPV/Hib Vaccines (PHASE3)
- Persistence and Booster Study of GSK Biologicals' Meningococcal Vaccine (GSK134612) in Healthy Children (PHASE3)
- Non-Inferiority of Meningococcal Vaccine GSK134612 Versus Mencevax™ in 2-10 Year Old Subjects (PHASE3)
- Safety & Immunogenicity Study of Meningococcal Vaccine GSK134612 Given With Priorix-Tetra™ to 12-23 Month-Old Children (PHASE3)
- Comparison of GSK Biologicals' Meningococcal Vaccine (GSK134612) and Licensed MenC-CRM197 Vaccine in Healthy Children (PHASE3)
- Study to Evaluate the Long-term Antibody Persistence of GlaxoSmithKline (GSK) Biologicals' MenACWY-TT Vaccine (GSK134612) Versus Mencevax ACWY in Healthy Adolescents and Adults and Booster Response to MenACWY-TT Vaccine Administered at 10 Years Post-primary Vaccination (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Meningococcal vaccine GSK134612 CI brief — competitive landscape report
- Meningococcal vaccine GSK134612 updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about Meningococcal vaccine GSK134612
What is Meningococcal vaccine GSK134612?
How does Meningococcal vaccine GSK134612 work?
What is Meningococcal vaccine GSK134612 used for?
Who makes Meningococcal vaccine GSK134612?
Is Meningococcal vaccine GSK134612 also known as anything else?
What drug class is Meningococcal vaccine GSK134612 in?
What development phase is Meningococcal vaccine GSK134612 in?
What are the side effects of Meningococcal vaccine GSK134612?
What does Meningococcal vaccine GSK134612 target?
Related
- Drug class: All Recombinant protein vaccine drugs
- Target: All drugs targeting Neisseria meningitidis serogroup B surface antigens
- Manufacturer: GlaxoSmithKline — full pipeline
- Therapeutic area: All drugs in Immunology / Infectious Disease
- Indication: Drugs for Prevention of meningococcal serogroup B disease in infants and children
- Also known as: Nimenrix®, MenACWY-TT, Nimenrix
- Compare: Meningococcal vaccine GSK134612 vs similar drugs
- Pricing: Meningococcal vaccine GSK134612 cost, discount & access